Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer

被引:21
作者
Pan, YZ
Xiao, XY
Zhao, D
Zhang, L
Ji, GY
Li, Y
Yang, BX
He, DC
Zhao, XJ
机构
[1] Jilin Univ, Sch Basic Med, Dept Reprod Pathophysiol, Res Ctr Prostate Dis, Changchun 130021, Peoples R China
[2] Beijing Normal Univ, Res Inst Proteom, Acad Life Sci, Res Inst Cytobiol, Beijing 100875, Peoples R China
关键词
prostate cancer; early diagnosis; protein chip; biomarker; serum;
D O I
10.1111/j.1745-7262.2006.00103.x
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Aim: To identify the serum biomarkers of prostate cancer (PCa) by protein chip and bioinformatics. Methods: Serum samples from 83 PCa patients and 95 healthy men were taken from a mass screening in Changchun, China. Protein profiling was carried out using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The data of spectra were analyzed using two bioinformatics tools. Results: Eighteen serum differential proteins were identified in the PCa group compared with the control group (P < 0.01). There were four proteins at the higher serum level and 14 proteins at the lower serum level in the PCa group. A decision tree classification algorithm that used an eight-protein mass pattern was developed to correctly classify the samples. A sensitivity of 92.0% and a specificity of 96.7% for the study group were obtained by comparing the PCa and control groups. Conclusion: We identified new serum biomarkers of PCa. SELDI-TOF MS coupled with a decision tree classification algorithm will provide a highly accurate and innovative approach for the early diagnosis of PCa.
引用
收藏
页码:45 / 51
页数:7
相关论文
共 17 条
[1]  
Adam BL, 2002, CANCER RES, V62, P3609
[2]  
Gu FL, 2003, CHINESE MED J-PEKING, V116, P1391
[3]  
GU FL, 2003, CHIN MED J, V116, P1643
[4]   Cancer statistics, 2003 [J].
Jemal, A ;
Murray, T ;
Samuels, A ;
Ghafoor, A ;
Ward, E ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26
[5]   Mass screening for prostate cancer: A comparative study in Natori, Japan and Changchun, China [J].
Kuwahara, M ;
Tochigi, T ;
Kawamura, S ;
Ogata, Y ;
Xu, N ;
Wang, HL ;
Zhang, HF ;
Li, SW ;
Li, XM ;
Zhao, XJ .
UROLOGY, 2003, 61 (01) :137-141
[6]   Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL [J].
Li, XM ;
Zhang, L ;
Li, J ;
Li, Y ;
Wang, HL ;
Ji, GY ;
Kuwahara, M ;
Zhao, XJ .
ASIAN JOURNAL OF ANDROLOGY, 2005, 7 (03) :323-328
[7]   Clinical proteomics: applications for prostate cancer biomarker discovery and detection [J].
Petricoin, EF ;
Ornstein, DK ;
Liotta, LA .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) :322-328
[8]  
Petricoin EF, 2002, J NATL CANCER I, V94, P1576
[9]   Use of proteomic patterns in serum to identify ovarian cancer [J].
Petricoin, EF ;
Ardekani, AM ;
Hitt, BA ;
Levine, PJ ;
Fusaro, VA ;
Steinberg, SM ;
Mills, GB ;
Simone, C ;
Fishman, DA ;
Kohn, EC ;
Liotta, LA .
LANCET, 2002, 359 (9306) :572-577
[10]  
Qu YS, 2002, CLIN CHEM, V48, P1835